Published in Hepatology on January 01, 2007
Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol (2010) 1.75
Hepatitis C virus and type 2 diabetes. World J Gastroenterol (2009) 1.57
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology (2011) 1.53
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
Liver diseases and metabolic syndrome. J Gastroenterol (2008) 1.33
Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology (2010) 1.13
Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology (2008) 1.11
Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol (2011) 1.10
Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World J Gastroenterol (2013) 1.02
Treatment failure in hepatitis C: mechanisms of non-response. J Hepatol (2008) 1.02
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut (2011) 1.00
Molecular mechanisms of insulin resistance in chronic hepatitis C. World J Gastroenterol (2009) 0.98
Ethnic variations in chronic liver diseases. Dig Dis Sci (2007) 0.95
Hepatitis C virus infection: molecular pathways to steatosis, insulin resistance and oxidative stress. Viruses (2009) 0.94
Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis. J Lipid Res (2009) 0.93
Predicting the probable outcome of treatment in HCV patients. Therap Adv Gastroenterol (2009) 0.92
Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action. Diabetes Care (2012) 0.91
Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response. Am J Clin Nutr (2012) 0.90
Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. World J Gastroenterol (2012) 0.90
Host factors determining the efficacy of hepatitis C treatment. J Gastroenterol (2012) 0.88
The interaction between insulin resistance, liver fibrosis and early virological response in Egyptian patients with chronic hepatitis C. Can J Gastroenterol (2012) 0.88
Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute? J Consult Clin Psychol (2012) 0.87
Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. Dig Dis Sci (2009) 0.84
Insulin resistance, steatosis, and fibrosis in Egyptian patients with chronic Hepatitis C virus infection. Saudi J Gastroenterol (2011) 0.84
Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci (2009) 0.83
Metabolic factors and chronic hepatitis C: a complex interplay. Biomed Res Int (2013) 0.82
Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients. J Hepatol (2010) 0.82
Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. Hepatol Int (2010) 0.82
Peroxisome proliferator-activated receptors and hepatitis C virus. Therap Adv Gastroenterol (2011) 0.79
Adrenal tumors in patients with chronic hepatitis C. Gastroenterol Hepatol (N Y) (2010) 0.79
Age- and Gender Dependent Liver Fat Content in a Healthy Normal BMI Population as Quantified by Fat-Water Separating DIXON MR Imaging. PLoS One (2015) 0.78
Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors. Hepat Res Treat (2010) 0.78
Host genetics, steatosis and insulin resistance among African Americans and Caucasian Americans with hepatitis C virus genotype-1 infection. Intervirology (2009) 0.78
Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease. J Clin Gastroenterol (2012) 0.77
Hepatitis C and insulin action: An intimate relationship. World J Hepatol (2016) 0.76
Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection. BMC Gastroenterol (2014) 0.76
Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review. World J Gastroenterol (2017) 0.75
Statin efficacy in the treatment of hepatitis C genotype I. J Res Med Sci (2014) 0.75
Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C. Dig Dis Sci (2017) 0.75
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med (2009) 8.06
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature (2005) 6.21
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Liver cirrhosis. Lancet (2008) 6.11
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13
Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol (2002) 4.56
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
Acute liver failure: Summary of a workshop. Hepatology (2008) 3.49
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology (2011) 3.46
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med (2008) 3.33
A multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000. J Pediatr (2006) 3.32
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology (2006) 2.96
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Gastrointestinal involvement in chronic granulomatous disease. Pediatrics (2004) 2.80
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology (2009) 2.78
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology (2002) 2.64
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
Clinical risk factors for portopulmonary hypertension. Hepatology (2008) 2.62
Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. J Infect Dis (2009) 2.53
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48
Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. Hepatology (2010) 2.48
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology (2009) 2.41
Optimal therapy of hepatitis C. Hepatology (2002) 2.40
Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology (2011) 2.39
A survey of liver transplantation from living adult donors in the United States. N Engl J Med (2003) 2.37
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Diagnosis and quantitation of fibrosis. Gastroenterology (2008) 2.20
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. J Hepatol (2011) 2.20
National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology (2002) 2.19
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology (2006) 2.11
Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. Transplantation (2005) 2.08
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol (2003) 2.05
Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology (2010) 1.98
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (2007) 1.92
Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch (2007) 1.91
Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology (2003) 1.87
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology (2015) 1.87
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Screening and outcomes in biliary atresia: summary of a National Institutes of Health workshop. Hepatology (2007) 1.81
A framework for management of hepatitis C in prisons. Ann Intern Med (2006) 1.80
Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood (2004) 1.77
Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis (2003) 1.76
Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology (2013) 1.76
Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet (2002) 1.76
Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology (2014) 1.74
Increased plasma interleukin-6 in donors is associated with lower recipient hospital-free survival after cadaveric organ transplantation. Crit Care Med (2008) 1.74
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology (2010) 1.74
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology (2007) 1.73
The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol (2007) 1.73
The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol (2013) 1.72
Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology (2007) 1.70
Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology (2010) 1.70
Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology (2012) 1.68
Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol (2008) 1.67
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology (2010) 1.67
A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. PLoS Pathog (2006) 1.66
Hepatitis C and renal disease: an update. Am J Kidney Dis (2003) 1.65
Helicobacter pylori moves through mucus by reducing mucin viscoelasticity. Proc Natl Acad Sci U S A (2009) 1.64
Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology (2005) 1.63
Relationship between surgeon volume and adverse outcomes after RYGB in Longitudinal Assessment of Bariatric Surgery (LABS) study. Surg Obes Relat Dis (2009) 1.63
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut (2013) 1.63
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol (2011) 1.62
Composite tissue allotransplantation: classification of clinical acute skin rejection. Transplantation (2006) 1.61
Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection? J Infect Dis (2013) 1.61
Causes of death in hyper-IgE syndrome. J Allergy Clin Immunol (2007) 1.61
Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. Gastroenterology (2010) 1.60
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol (2011) 1.59